Several studies have demonstrated that patients with tumors exhibiting positive PD-L1 expression scores show higher response rates and greater therapeutic benefits to ICIs across various cancer types, including NSCLC, UC, and others [9,420,421]. Here, CD274 is linked to non-small cell lung carcinoma.